Morepen Laboratories Limited — Updates, 01-04-2025: Press Release

Morepen Laboratories Limited has secured approval from China's National Medical Products Administration for its Loratadine API, marking a pivotal step in its entry into the Chinese pharmaceutical market. With over 80% market share in the US generics market for Loratadine, valued at Rs. 650 crores in exports, this approval reinforces Morepen's status as a leading global manufacturer of antihistamines. The company aims to capitalize on the growing demand for high-quality anti-allergy APIs in China, following its longstanding reputation for regulatory compliance and quality excellence. This development is a significant boost for Morepen, positioning it to expand its footprint across regulated and emerging markets while maintaining its leadership in the healthcare sector. Investors should view this as a positive growth opportunity for the company moving forward.